^
Association details:
| Biomarker: | ACSL3 overexpression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | ezetimibe/simvastatin (HMG-CoA reductase inhibitor, Cholesterol absorption inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non-small cell lung cancer
Published date:
10/08/2020
Excerpt:
...patients with high expression levels of ACSL3 following statin treatment display better prognosis than those not treated with statins....22.22% of patients that overexpress ACSL3 and are having benefits from statin treatment. By contrast, there are a 57.77% of patients that overexpress ACSL3 and would advantage from statin antiproliferative action...found that patients with high expression levels of ACSL3 displayed a clinical benefit of statins treatment.
DOI:
10.1002/1878-0261.12816
